Structural and functional brain magnetic resonance imaging findings of chemothera

描述(申请人提供)：乳腺癌是美国女性确诊的头号癌症，也是导致癌症死亡的第二大原因。辅助化疗已被证明可以降低乳腺癌复发和死亡的风险。然而，老年人化疗毒性的风险增加，包括与治疗相关的死亡风险增加。目前，关于化疗和毒性对乳腺癌患者大脑结构和功能的影响只有初步证据。然而，这项先前的研究并没有专门研究老年女性。因此，有必要建立一种具有可重复性生物标志物的更灵敏的检测方法，以识别化疗毒性风险较高的老年乳腺癌患者。我们的长期目标是确定与老年癌症患者化疗毒性相关的高度敏感和可重复性的脑MRI生物标志物。为了实现这一目标，本研究的目标是定义脑MRI发生的变化，并确定老年乳腺癌患者的脑MRI变化与化疗毒性之间的关系。我们的目标是1)确定接受辅助化疗的老年女性乳腺癌患者的脑MRI结构和功能变化，以及2)确定脑MRI结构和功能变化的严重程度与化疗毒性之间的关系。我们预计患者脑部核磁共振成像结构和功能改变的严重性将 与化疗毒性的严重程度相关。这项拟议的研究意义重大，因为它关注的是患有乳腺癌的老年女性脑部MRI变化与化疗毒性之间的未知关系。它的创新性是因为它提出了先进的磁共振技术来研究和识别新的潜在生物标记物，用于老年人的化疗毒性。 乳腺癌。这将有助于阐明化疗毒性导致认知能力下降的潜在病理生理机制，从而产生积极的影响。这项先导性研究产生的数据也将有助于为未来对老年人认知和化疗的大规模研究奠定基础。

DESCRIPTION (provided by applicant): Breast cancer is the leading cancer diagnosed among woman in the US and is the second leading cause of cancer deaths. Adjuvant chemotherapy has been proven to decrease the risks of relapse and mortality from breast cancer. However, older adults are at increased risk for chemotherapy toxicity, including an increased risk of treatment-related mortality. At present, there is only preliminary evidence regarding which brain structures and functions are affected by chemotherapy and toxicity in breast cancer patients. However, this prior research did not specifically study older women. Thus, there is a need to establish a more sensitive test that has reproducible biomarkers, to identify the older breast cancer patients who are at higher risk for chemotherapy toxicity Our long term goal is to identify highly sensitive and reproducible brain MRI biomarkers that are associated with chemotherapy toxicity in aging cancer patients. Toward that goal, the objective of this study is to define the changes that occur on brain MRI and to determine the relationship between brain MRI changes and chemotherapy toxicity in older adults with breast cancer. We aim to 1) define structural and functional changes that occur on brain MRI of older women with breast cancer receiving adjuvant chemotherapy and; 2) determine the relationship between the severity of structural and functional changes on brain MRI and chemotherapy toxicity. We expect that the severity of structural and functional changes to the brain MRI in our patients will correlate with the severity of chemotherapy toxicity. The proposed study is significant because it focuses on the unknown relationship between brain MRI changes and chemotherapy toxicity in older women with breast cancer. It is innovative because it proposes advanced MRI techniques to study and identify the novel potential biomarkers for chemotherapy toxicity in older adults with breast cancer. It will have a positive impact by helping to clarify the underlying pathophysiology of cognitive decline caused by chemotherapy toxicity. The data generated from this pilot study will also help to serve as a foundation for future large scale studies of cognition and chemotherapy in older adults.